Literature DB >> 26034079

The Boston Keratoprosthesis type 1 as primary penetrating corneal procedure.

Raphaëlle Fadous1, Samuel Levallois-Gignac1, Louis Vaillancourt1, Marie-Claude Robert1, Mona Harissi-Dagher1.   

Abstract

BACKGROUND/AIMS: Penetrating keratoplasty (PK) has a poor prognosis in certain corneal eye diseases. The safety and efficacy of Boston type 1 Keratoprosthesis (KPro) surgery as a primary penetrating corneal surgery were evaluated for patients with corneal blindness and poor prognosis for PK.
METHODS: In this retrospective interventional comparative study, all patients who underwent KPro implantation by a single surgeon between October 2008 and March 2011 at the Centre Hospitalier de l'Université de Montréal were divided into two groups. Thirty patients with KPro as a primary procedure (group 1) were compared with 40 patients who had PK prior to KPro (group 2). A chart review examining preoperative and postoperative best-corrected visual acuity (BCVA), intraoperative and postoperative complications and KPro retention rate over the first postoperative year was performed.
RESULTS: Preoperative BCVA was 20/200 or better in 10% of eyes in group 1 (range 20/150 light perception (LP)), and in 5% of eyes in group 2 (range 20/100 LP; p=0.42). BCVA was significantly better in group 1 throughout the follow-up (p<0.05). At 12 months, 87% and 63% of eyes achieved a BCVA better than 20/200 in groups 1 and 2, respectively (p<0.05). The complication rates and retention rate were similar in the two groups.
CONCLUSIONS: This study demonstrates that the Boston KPro implantation may be successful as a primary procedure in patients at high risk of failure with traditional PK. Further, there appears to be a visual benefit to primary KPro surgery. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Anterior chamber; Cornea; Prosthesis; Treatment Surgery

Mesh:

Year:  2015        PMID: 26034079     DOI: 10.1136/bjophthalmol-2014-306161

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  Management of Congenital Aniridia-Associated Keratopathy: Long-Term Outcomes from a Tertiary Referral Center.

Authors:  Ghasem Yazdanpanah; Kelley J Bohm; Omar M Hassan; Faris I Karas; Abdelrahman M Elhusseiny; Manachai Nonpassopon; Muanploy Niparugs; Elmer Y Tu; Joel Sugar; Mark I Rosenblatt; Maria S Cortina; Ali R Djalilian
Journal:  Am J Ophthalmol       Date:  2019-11-12       Impact factor: 5.258

Review 2.  The treatment of end-stage corneal disease: penetrating keratoplasty compared with Boston type 1 keratoprosthesis.

Authors:  Steven Bonneau; C Maya Tong; Yelin Yang; Mona Harissi-Dagher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-06       Impact factor: 3.535

3.  Experimental study on the biocompatibility of keratoprosthesis with improved titanium implant.

Authors:  Li Li; Hua Jiang; Li-Qiang Wang; Yi-Fei Huang
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

4.  Five year outcomes of Boston type I keratoprosthesis as primary versus secondary penetrating corneal procedure in a matched case control study.

Authors:  Kai B Kang; Faris I Karas; Ruju Rai; Joelle A Hallak; Joann J Kang; Jose de la Cruz; Maria S Cortina
Journal:  PLoS One       Date:  2018-02-06       Impact factor: 3.240

Review 5.  Boston Type 1 Keratoprosthesis: Updated Perspectives.

Authors:  Manachai Nonpassopon; Muanploy Niparugs; Maria Soledad Cortina
Journal:  Clin Ophthalmol       Date:  2020-04-29

Review 6.  Current Perspectives on Corneal Transplantation (Part 2).

Authors:  Yee Ling Wong; Siyin Liu; Andrew Walkden
Journal:  Clin Ophthalmol       Date:  2022-03-04

Review 7.  Paraproteinemic keratopathy in monoclonal gammopathy of undetermined significance treated with primary keratoprosthesis: Case report, histopathologic findings, and world literature review.

Authors:  Homer H Chiang; Rebekah S Wieland; Thomas S Rogers; Pamela C Gibson; George Atweh; Gregory McCormick
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.